Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of the drug is set to continue. Announced in the company’s Q4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback